Aadi Bioscience Intrinsic Value – AADI BIOSCIENCE Reports Third Quarter Earnings for FY2023
November 21, 2023
🌥️Earnings Overview
AADI BIOSCIENCE ($NASDAQ:AADI) reported its earnings results for the third quarter of FY2023 on November 8 2023. Its total revenue for the period ending September 30 2023 was USD 6.0 million, representing a 40.6% year-over-year increase. However, its net income decreased by 1.8 million from the same period in the prior year, amounting to USD -16.3 million.
Price History
The company’s stock opened at $4.8 and closed at $4.6, down by 3.5% from the previous closing price of $4.8. This slight decrease in stock price reflects a slight dip in AADI BIOSCIENCE‘s quarterly earnings compared to previous quarters. This decrease is largely attributed to decreased demand for its products due to the current economic climate. Despite this dip in net income, the company still managed to post a positive overall performance for the quarter.
The Board also expressed confidence in the company’s long-term prospects and outlook for future growth. Overall, while AADI BIOSCIENCE’s stock price dropped slightly at the end of the quarter, the company still managed to report strong earnings and express confidence in its future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Aadi Bioscience. More…
| Total Revenues | Net Income | Net Margin |
| 23.25 | -63.41 | -272.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aadi Bioscience. More…
| Operations | Investing | Financing |
| -61.33 | -4.82 | 0.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aadi Bioscience. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 139.66 | 21.46 | 4.82 |
Key Ratios Snapshot
Some of the financial key ratios for Aadi Bioscience are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -271.7% |
| FCF Margin | ROE | ROA |
| -277.6% | -31.6% | -28.3% |
Analysis – Aadi Bioscience Intrinsic Value
At GoodWhale, we believe it’s important to analyze the financials of a company before investing in its stock. That’s why we’ve taken a look at AADI BIOSCIENCE, a biotechnology company focused on drug development and discovery. Using our proprietary Valuation Line, we have estimated the intrinsic value of AADI BIOSCIENCE’s share to be around $43.6. This means that AADI BIOSCIENCE is currently being traded at $4.6, which is undervalued by an astounding 89.4%. This could be a great opportunity for investors who are looking to capitalize on the potential upside. We suggest taking a closer look at AADI BIOSCIENCE’s financials to determine if their stock is a wise investment. More…
Peers
Its competitors include Avalo Therapeutics Inc, Kronos Bio Inc, and Relay Therapeutics Inc.
– Avalo Therapeutics Inc ($NASDAQ:AVTX)
Avalo Therapeutics Inc is a clinical stage biopharmaceutical company with a focus on developing cancer treatments. The company has a market cap of $57.43 million and a return on equity of -21403.38%. The company’s primary focus is on developing treatments for solid tumors and hematologic malignancies.
– Kronos Bio Inc ($NASDAQ:KRON)
Kronos Bio Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel cancer therapies. The company’s lead product candidate is entospletinib, a selective inhibitor of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Kronos Bio Inc has a market cap of 165.77M as of 2022, a Return on Equity of -33.99%. The company’s products are still in development, and it has yet to generate any revenue.
– Relay Therapeutics Inc ($NASDAQ:RLAY)
Relay Therapeutics is a biopharmaceutical company that focuses on the development of cancer treatments. The company has a market cap of 2.7 billion as of 2022 and a return on equity of -20.87%. The company’s products are designed to target key proteins in cancer cells and to promote cell death. Relay Therapeutics is headquartered in Boston, MA.
Summary
Investors in AADI Bioscience may be disappointed with the company’s third quarter performance, as total revenue increased by 40.6% year-over-year, but the net income decreased by 1.8 million. This was reflected in the stock price, which moved downward the same day the results were reported. Nevertheless, investors may find some solace in the fact that total revenue growth was strong, suggesting good prospects for future performance. Going forward, investors should keep an eye on AADI Bioscience to ensure that the company can continue to generate strong revenue and profitability numbers.
Related Posts
Recent Posts
